Therapeutic Effect of Cimetidine in Patients Undergoing Haemodialysis

Overview

Journal Br Med J

Specialty General Medicine

Date 1979 Mar 10

PMID 435708

Citations 9

Authors

R H Jones

M R Lewin

V Parsons

Affiliations

Soon will be listed here.

Abstract

Blood concentrations of cimetidine were measured and the therapeutic effect of the drug assessed patients undergoing maintenance haemodialysis. Thirteen patients were given a single oral 200-mg dose of cimetidine a mean of 2.7 hours before the start of dialysis. Dialysing for 6--12-6 m2 hours led to a mean fall of 71% in blood cimetidine concentration during haemodialysis. Nine patients with various upper gastrointestinal lesions diagnosed endoscopically were treated for up to six weeks with a reduced cimetidine dose of 200 mg 12-hourly; two patients received two courses of treatment. Repeat endoscopy after treatment disclosed satisfactory healing, and the drug did not accumulate. This lower dose regimen is recommended for patients receiving dialysis who develop upper gastrointestinal lesions for which a histamine H2-receptor antagonist is indicated.

Citing Articles

Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Gladziwa U, Klotz U Clin Pharmacokinet. 1993; 24(4):319-32.

PMID: 8098275 DOI: 10.2165/00003088-199324040-00005.

Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.

Gladziwa U, Koltz U Clin Pharmacokinet. 1994; 27(5):393-408.

PMID: 7851056 DOI: 10.2165/00003088-199427050-00006.

The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.

Larsson R, ERLANSON P, Bodemar G, Walan A, BERTLER A, Fransson L Br J Clin Pharmacol. 1982; 13(2):163-70.

PMID: 7059413 PMC: 1402003. DOI: 10.1111/j.1365-2125.1982.tb01351.x.

Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.

Larsson R, ERLANSON P, Bodemar G, Norlander B, Fransson L, Strouth L Eur J Clin Pharmacol. 1982; 21(4):325-30.

PMID: 7056278 DOI: 10.1007/BF00637621.

Clinical pharmacokinetics of cimetidine.

Somogyi A, Gugler R Clin Pharmacokinet. 1983; 8(6):463-95.

PMID: 6418428 DOI: 10.2165/00003088-198308060-00001.

References

Doherty C, OConnor F, Buchanan K, McGeown M . Cimetidine for duodenal ulceration in patients undergoing haemodialysis. Br Med J. 1977; 2(6101):1506-8. PMC: 1632805. DOI: 10.1136/bmj.2.6101.1506. View

Bodemar G, Walan A . Cimetidine in the treatment of active duodenal and prepyloric ulcers. Lancet. 1976; 2(7978):161-4. DOI: 10.1016/s0140-6736(76)92342-4. View

Langman M, Cooke A . Gastric and duodenal ulcer and their associated diseases. Lancet. 1976; 1(7961):680-3. DOI: 10.1016/s0140-6736(76)92790-2. View

Gray G, SMITH I, McKenzie I, CREAN G, Gillespie G . Oral cimetidine in severe duodenal ulceration. A double-blind controlled trial. Lancet. 1977; 1(8001):4-7. DOI: 10.1016/s0140-6736(77)91650-6. View

GRIMSON T . Reactions to cimetidine. Lancet. 1977; 1(8016):858. DOI: 10.1016/s0140-6736(77)92808-2. View

MacDougall B, Bailey R, Williams R . H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials. Lancet. 1977; 1(8012):617-9. DOI: 10.1016/s0140-6736(77)92055-4. View

Burland W, Duncan W, HESSELBO T, Mills J, Sharpe P, Haggie S . Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol. 1975; 2(6):481-6. PMC: 1402643. DOI: 10.1111/j.1365-2125.1975.tb00564.x. View

Frost F, Rahbek I, RUNE S, Jensen K, KRAG E, Rask-Madsen J . Cimetidine in patients with gastric ulcer: a multicentre controlled trial. Br Med J. 1977; 2(6090):795-7. PMC: 1632024. DOI: 10.1136/bmj.2.6090.795. View

Chisholm G, Mee A, Williams G, Castro J, Baron J . Peptic ulceration, gastric secretion, and renal transplantation. Br Med J. 1977; 1(6077):1630-3. PMC: 1607768. DOI: 10.1136/bmj.1.6077.1630. View

10.

Korman M, Laver M, Hansky J . Hypergastrinaemia in chronic renal failure. Br Med J. 1972; 1(5794):209-10. PMC: 1789180. DOI: 10.1136/bmj.1.5794.209. View

11.

Shepherd A, Stewart W, Wormsley K . Peptic ulceration in chronic renal failure. Lancet. 1973; 1(7816):1357-9. DOI: 10.1016/s0140-6736(73)91677-2. View

12.

Gordon E, Johnson A, Williams G . Gastric assessment of prospective renal-transplant patients. Lancet. 1972; 1(7744):226-9. DOI: 10.1016/s0140-6736(72)90623-x. View

13.

Wiener S, VERTES V, Shapiro H . The upper gastrointestinal tract in patients ungergoing chronic dialysis. Radiology. 1969; 92(1):110-4. DOI: 10.1148/92.1.110. View

14.

Johnson L . Source of the histamine released during damage to the gastric mucosa by acetic acid. Gastroenterology. 1968; 54(1):8-15. View

15.

Katz A, HAMPERS C, MERRILL J . Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Analysis of 195 patients, with observations on the effects of chronic dialysis, kidney transplantation and subtotal parathyroidectomy. Medicine (Baltimore). 1969; 48(5):333-74. View

16.

Vandevelde A, Mauceri A, Johnson 3rd J . 5-fluorocytosine in the treatment of mycotic infections. Ann Intern Med. 1972; 77(1):43-51. DOI: 10.7326/0003-4819-77-1-43. View

17.

Moore T, Thompson D, Glassock R . Elevation in urinary and blood histamine following clinical renal transplantation. Ann Surg. 1971; 173(3):381-8. PMC: 1397377. DOI: 10.1097/00000658-197103000-00008. View

18.

Moody F, Cheung L, Simons M, Zalewsky C . Stress and the acute gastric mucosal lesion. Am J Dig Dis. 1976; 21(2):148-54. DOI: 10.1007/BF01072062. View

19.

van Cutsem J, THIENPONT D . Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy. 1972; 17(6):392-404. DOI: 10.1159/000220875. View

20.

CLENDINNEN B, Reeder D, BRANDT Jr E, Thompson J . Effect of nephrectomy on the rate and pattern of the disappearance of exogenous gastrin in dogs. Gut. 1973; 14(6):462-7. PMC: 1412732. DOI: 10.1136/gut.14.6.462. View